Last edition
News about "rh-insulin"
US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI
The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.
Rh-Insulin | 29/11/2025 | By Dineshwori | 225
Biocon Biologics Scales Up Insulin Access in Malaysia
Biocon Biologics has announced that its Malaysian subsidiary has crossed the milestone of supplying over 100 million recombinant human insulin cartridges to Malaysia’s Ministry of Health, reinforcing its commitment to affordable and accessible diabetes care.
Rh-insulin | 30/06/2025 | By Mrinmoy Dey | 296
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy